STOCK TITAN
  1. Home
  2. News
  3. HALO

Halozyme Therapeutics, Inc. - HALO STOCK NEWS

Welcome to our dedicated page for Halozyme Therapeutics news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics stock.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company headquartered in San Diego, CA, focused on developing and commercializing innovative oncology therapies. The company's core mission is to enhance the efficacy of cancer treatments by targeting the tumor microenvironment, particularly through its lead investigational drug, pegph20. This drug aims to improve the penetration of co-administered cancer therapies into solid tumors, potentially making existing treatments more effective.

Halozyme's proprietary ENHANZE® drug delivery technology platform has garnered significant attention and partnerships with leading pharmaceutical companies such as Roche, Pfizer, Janssen, Baxalta, AbbVie, and Lilly. This technology facilitates the subcutaneous administration of biologics and small molecule compounds that are traditionally delivered intravenously, potentially allowing for quicker and more convenient therapy delivery.

The company has built a strong foundation of value-driving partnerships and continues to innovate in drug-device combination products using advanced auto-injector technology to improve patient convenience, comfort, and adherence. Halozyme's commercial portfolio includes proprietary products like Hylenex® and XYOSTED®, and ongoing product development in partnership with pharmaceutical companies such as Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Recent achievements highlight Halozyme’s growth and innovation. Notably, the U.S. FDA approved Takeda’s HYQVIA®, co-formulated with ENHANZE®, for the maintenance therapy of chronic inflammatory demyelinating polyneuropathy (CIDP), underscoring the potential of Halozyme’s technology to enhance treatment efficacy. Another milestone includes the Japanese Ministry of Health's approval of argenx's VYVDURA® for generalized myasthenia gravis, demonstrating global expansion and acceptance of ENHANZE®-enabled treatments.

Financially, Halozyme continues to show robust growth. The company reported strong revenue and earnings growth in the first quarter of 2024, reaffirming its positive financial guidance for the year. Halozyme also announced a new $750 million share repurchase program, indicating confidence in sustained growth.

Halozyme's efforts in maintaining an extensive patent portfolio, including the recent grant of European Patent No. 4269578 for its ENHANZE® rHuPH20 product, further solidify its market position and prospects for long-term revenue durability. The company's strategic collaborations and commitment to innovative patient solutions make it a significant player in the biopharmaceutical industry.

News

Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will release its Q4 and full year 2023 financial and operating results on February 20, 2024. A conference call will be held to discuss the results, and a live webcast and replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences earnings
-
News

Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Takeda received European Commission approval for HYQVIA® co-formulated with Halozyme's ENHANZE® drug delivery technology as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous immunoglobulin therapy. HYQVIA® also received FDA approval as maintenance therapy for adults with CIDP. The approval allows for the administration of HYQVIA® by a healthcare professional or self-administered in the patient's home after appropriate training. The centralized marketing authorization for HYQVIA® in CIDP is valid in all EU member states, Iceland, Liechtenstein, Norway, and Northern Ireland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
none
-
News

Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

Rhea-AI Summary
Halozyme Therapeutics, Inc. announced that argenx received approval from Japan's Ministry of Health, Labour and Welfare for VYVDURA® injection co-formulated with Halozyme's ENHANZE® drug delivery technology for the treatment of adult patients with generalized myasthenia gravis. The approval includes the option for patient self-administration at home. The approval is based on positive results from the Phase 3 ADAPT-SC study, demonstrating a reduction in total immunoglobulin G levels comparable to VYVGART® IV in adult gMG patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none
News

Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Takeda received FDA approval for HYQVIA® co-formulated with Halozyme's ENHANZE® drug delivery technology for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. HYQVIA® is the only FDA-approved combination of immunoglobulin (IG) and hyaluronidase for subcutaneous immunoglobulin (SCIG) infusion. The treatment can be administered by a healthcare professional in various settings and can also be self-administered after training.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
fda approval
-
News

Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Roche received European Commission marketing authorization of Tecentriq® SC co-formulated with ENHANZE®, reducing treatment time by approximately 80% compared to standard intravenous infusion. The approval applies to all approved indications of Tecentriq® IV and represents the EU's first PD-(L)1 cancer immunotherapy for subcutaneous injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
none
-
News

Halozyme to Host Investor Business Forum and Long-Term Outlook Call

Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host an Investor Business Forum and Long-Term Outlook Call on January 17, 2024, to provide detailed guidance on the revenue durability of its ENHANZE® drug delivery technology and present 2024 financial guidance as well as long-term financial outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
News

Halozyme to Present at Upcoming Investor Conferences

Rhea-AI Summary
Halozyme Therapeutics, Inc. (HALO) senior leadership team to present at Piper Sandler 35th Annual Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference. CFO Nicole LaBrosse and President/CEO Helen Torley to host investor meetings in New York and Miami, respectively, on November 29th, 2023. Live audio webcast and replays available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences
-
News

Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

Rhea-AI Summary
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that argenx received European Commission approval for VYVGART® SC, a subcutaneous form of the drug for treating generalized myasthenia gravis in adult patients. This approval allows for patient self-administration, following the U.S. approval in June. VYVGART® SC is a combination of efgartigimod alfa and Halozyme's ENHANZE® drug delivery technology, approved based on positive results from the Phase 3 ADAPT-SC study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
News

HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Rhea-AI Summary
Halozyme Therapeutics, Inc. reported a 15% YoY increase in royalty revenue to a record $114.4 million. They also announced the acceleration of the remaining $250 million share repurchase through ASR. GAAP diluted EPS was $0.61 and non-GAAP diluted EPS was $0.75. The company maintained its revenue guidance and raised its 2023 EBITDA guidance to $430-$445 million and non-GAAP EPS guidance to $2.70-$2.80.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.04%
Tags
earnings
News

Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

Rhea-AI Summary
Halozyme Therapeutics announces a collaboration and license agreement with Acumen Pharmaceuticals for the use of their ENHANZE® drug delivery technology in the development of ACU193, a monoclonal antibody candidate for the treatment of early Alzheimer's disease. Acumen will make upfront and milestone payments to Halozyme, and Halozyme will receive royalties on net sales of commercialized medicines with the ENHANZE® technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none

FAQ

What is the current stock price of Halozyme Therapeutics (HALO)?

The current stock price of Halozyme Therapeutics (HALO) is $53.76 as of January 8, 2025.

What is the market cap of Halozyme Therapeutics (HALO)?

The market cap of Halozyme Therapeutics (HALO) is approximately 6.7B.

What is Halozyme Therapeutics' main focus?

Halozyme Therapeutics focuses on developing and commercializing novel oncology therapies and enhancing the delivery of biologics and small molecule compounds.

What is the ENHANZE® technology?

ENHANZE® is Halozyme's proprietary drug delivery technology that facilitates the subcutaneous administration of drugs traditionally delivered intravenously, improving treatment convenience and patient adherence.

Who are Halozyme's key partners?

Halozyme has partnerships with several leading pharmaceutical companies, including Roche, Pfizer, Janssen, Baxalta, AbbVie, and Lilly.

What recent approvals have Halozyme's technologies received?

Recent approvals include FDA approval of Takeda’s HYQVIA® for CIDP and Japanese Ministry of Health's approval of argenx's VYVDURA® for generalized myasthenia gravis.

What are some of Halozyme's proprietary products?

Halozyme's proprietary products include Hylenex® and XYOSTED®.

Where is Halozyme headquartered?

Halozyme is headquartered in San Diego, CA, with additional offices in Ewing, NJ, and Minnetonka, MN.

How does Halozyme's ENHANZE® technology benefit patients?

ENHANZE® technology allows for faster, more convenient subcutaneous drug administration, potentially enhancing treatment efficacy and improving patient adherence.

What is the significance of Halozyme's recent European patent grant?

The recent grant of European Patent No. 4269578 strengthens Halozyme's patent estate, extending the durability of its ENHANZE® technology portfolio and maintaining original royalty rates for DARZALEX® SC in Europe through 2029.

What financial outlook did Halozyme recently provide?

Halozyme raised its 2024 financial guidance and updated its 5-year financial outlook based on the new European patent, reflecting expected sustained revenue growth and profitability.

What is pegph20?

Pegph20 is Halozyme’s lead investigational drug, designed to enhance the penetration of cancer therapies into solid tumors, potentially improving their efficacy.
Stock HALO logo
Halozyme Therapeutics, Inc.

Nasdaq:HALO

HALO Rankings

#1080 Ranked by Market Cap
N/A Ranked by Dividends

HALO Stock Data

6.70B
125.87M
1.06%
100.73%
6.91%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO